Cytoblastin Injection
Vinblastine
10ml
Cipla Ltd.
| Pack size | 1 |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price |
Available as:
Indications
Cytoblastin Injection is used for:
Histiocytic lymphoma; Hodgkin's disease; Kaposi's sarcoma; Letterer-Siwe disease; Lymphocytic lymphoma; Mycosis fungoides; Testicular cancer
Adult Dose
Intravenous
Cancers
Testicular CA, Squamous cell CA of head & neck, Hodgkin's Dz, Kaposi's sarcoma; histiocytic lymphoma, mycosis fungoides, & Letterer-Siwe disease (histiocytosis X)
General Dosing Ranges
3.7-18 mg/sq.meter/day IV q7-10d
1st dose 3.7 mg/sq.meter/day IV
Incr by 1.85 mg/sq.meter qweek until WBC equal 3000/cu.mm
NMT 18.5 mg/sq.meter
Hepatic impairment
Decrease dose by half if bilirubin >3 mg/dL [>51 umol/L]
Child Dose
Intravenous
Cancers
Testicular CA, Squamous cell carcinoma CA of head & neck, Hodgkin's Dz, Kaposi's sarcoma; histiocytic lymphoma, mycosis fungoides, & Letterer-Siwe disease (histiocytosis X)
General dosing ranges
2.5- 12.5 mg/sq meter IV q7-10d
1st dose 2.5 mg/sq.meter IV
Incr by 1.25 mg/sq.meter qWeek until WBC = 3000/cu.mm
No more than 12.5 mg/sq.meter
Renal Dose
Administration
IV Preparation
IV push
1 mg/mL (dose/syringe); max syringe size for IVP is a 30 mL syringe & syringe should be <75% full
Powder: reconstitute w/ 10 mL NS or bacteriostatic NS to obtain 1 mg/mL soln
Continuous infusion: 250-1000 mL D5W or NS (dose)
Contra Indications
Severe bone marrow suppression; presence of bacterial infection; maglignant cell infiltration of bone marrow; Inj into extremity with poor circulation; porphyria; granulocytopenia. Elderly with cachexia or extreme skin ulcerations. Pregnancy; lactation. Intrathecal use may result in death.
Precautions
Hepatic impairment; neurotoxicity; ischemic heart disease; preexisting pulmonary dysfunction; extravasation may cause tissue damage and pain. Discontinue immediately if extravasation occurs, with local Inj of hyaluronidase and local heat application to decrease discomfort and risk of cellulitis; remaining Inj to be injected into another vein. Routine prophylaxis against constipation recommended especially in high doses. Nadir in leukocyte count occur 4-10 days after vinblastine admin; recovery observed 7-14 days after treatment.
Lactation: not known if excreted in breast milk, do not nurse
Pregnancy-Lactation
Interactions
Possible increase in vinblastine levels with aprepitant. Reduced vinblastine metabolism with miconazole. Variable interactions with phenytoin, monitor serum phenytoin levels. Reduced immune response with vaccines. Additive myelotoxicity with zidovudine. Concurrent admin of vinblastine with CYP3A inhibitors may cause an earlier onset and/or an increased severity of side effects.
Potentially Fatal: Increased toxicity of vinblastine with erythromycin. Increased neurotoxicity and myelotoxicity with azole antifungals e.g. itraconazole and posaconazole. Increased risk of severe neutropenia with ritonavir. Increased risk of acute pulmonary toxicity with mitomycin. Increased toxicity when ganciclovir is given with, immediately before or after vinblastine.
Adverse Effects
Side effects of Vinblastine :
1-10%
Anemia,Leukopenia,Myelosuppression,Alopecia
Frequency Not Defined
Peripheral neuropathy,Hypertension,Bronchospasm,Nausea,Vomiting,Anorexia,Diarrhea,Constipation,Paralytic ileus,Jaw pain,Aspermia,Amenorrhea
Mechanism of Action
Vinblastine is M phase specific. It binds to microtubular proteins and arrests mitosis at the metaphase by disrupting mitotic spindle formation. It blocks glutamic acid utilization, thus inhibiting purine synthesis, the citric acid cycle, and the formation of urea. It may also interfere with nucleic acid and protein synthesis.
Note
Cytoblastin 10ml Injection manufactured by Cipla Ltd.. Its generic name is Vinblastine. Cytoblastin is availble in Nepal.
Farmaco Nepal drug index information on Cytoblastin Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.